Wednesday, February 01, 2006

NABI

Nabi Biopharmaceuticals tonight announcing it's product Civacir an antibody for preventing hepatitis C Virus reinfection in liver transplants has recieved a fast track review by the FDA. The stock was up in after hours trading so keep this stock on your trading radar.

Budd Foxx

0 Comments:

Post a Comment

<< Home